Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression

Archives of General Psychiatry

Volumn 59, Issue 3, 2002, Pages 250-261

  Saxena, Sanjaya ^a   Brody, Arthur L ^a   Ho, Matthew L ^a   Alborzian, Shervin ^a   Maidment, Karron M ^a   Zohrabi, Narineh ^a   Ho, Mai K ^a   Huang, Sung Cheng ^b   Wu, Hsiao Ming ^b   Baxter Jr , Lewis R ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; CORPUS STRIATUM; DEPRESSION; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSION; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY;

EID: 0036192696     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.59.3.250     Document Type: Article

References (68)

1. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: A comparison with rates in unipolar depression and in normal controls
2. Cerebral glucose metabolic rates in non-depressed obsessive-compulsives
3. Cerebral glucose metabolic rates in obsessive-compulsive disorder
4. Cerebral glucose metabolism in childhood onset obsessive-compulsive disorder
5. Obsessional slowness: Functional studies with positron emission tomography
6. Cerebral glucose metabolism in childhood onset obsessive-compulsive disorder: Revisualization during pharmacotherapy
7. Local cerebral glucose metabolic rates in obsessive-compulsive disorder: Patients treated with clomipramine
8. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder
9. [18F]-FDG-PET study in obsessive-compulsive disorder: A clinical/metabolic correlation study after treatment
10. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment of obsessive-compulsive disorder
11. Brain mediation of obsessive-compulsive disorder symptoms: Evidence from functional brain imaging studies in the human and nonhuman primate
12. Reduction of prefrontal cortex glucose metabolism common to 3 types of depression
13. Left prefrontal glucose hypometabolism in the depressed state: A confirmation
14. The anatomy of melancholia: Focal abnormalities of cerebral blood flow in major depression
15. Frontal and parietal metabolic disturbances in unipolar depression
16. Paralimbic hypoperfusion in unipolar depression
17. Regional cerebral glucose metabolism in major depressive disorder
18. Regional cerebral blood flow and lateralized hemispheric dysfunction in depression
19. A functional anatomical study of unipolar depression
20. Functional neuroimaging studies of depression: The anatomy of melancholia
21. Reciprocal limbic-cortical function and negative mood: Converging PET findings in depression and normal sadness
22. Effect of sertraline on regional metabolic rate in patients with affective disorder
23. Cerebral metabolic rates for glucose in mood disorders: Studies with positron emission tomography and fluorodeoxyglucose F18
24. Brain imaging studies of antidepressant treatments
25. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine
26. Regional cerebral blood flow in mood disorders, III: Treatment and clinical response
27. The epidemiology and clinical features of obsessive-compulsive disorder
28. The cross national epidemiology of obsessive-compulsive disorder
29. Depressive psychosis in the obsessional neurotic
30. Obsessional symptoms and obsessional personality traits in patients with depressive illnesses
31. Multicenter double-blind trial comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders
32. The Yale-Brown Obsessive-Compulsive Scale, I: Development, use, and reliability
33. Diagnosis and rating scale for depression
34. A rating scale for anxiety
35. The global assessment scale: A procedure for measuring overall severity of psychiatric disturbance
36. Paroxetine vs clomipramine in the treatment of obsessive-compulsive disorder
37. Pharmacotherapy of obsessive-compulsive disorder: Experience with fluoxetine
38. Analysis of the Hamilton Depression Rating Scale: Factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression
39. Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations
40. Mirtazapine: Efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder
41. Cerebral metabolism in major depression and obsessive-compulsive disorder occurring separately and concurrently
42. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy
43. Comparing functional (PET) images: The assessment of significant change
44. Functional anatomy of language processing: Neuroimaging and the problem of individual variability
45. A general technique for interstudy registration of multifunction and multimodality images
46. Reliability of drawing regions of interest for positron emission tomography
47. Cytoarchitectonic definition of prefrontal areas in the normal human cortex, II: Variability in locations of areas 9 and 46 and relationship to the Tailarach Coordinate System
48. Statistical parametric maps in functional imaging: A general linear approach
49. Spatial registration and normalization of images
50. Functional anatomy of obsessive-compulsive phenomena
51. Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder
52. Neural correlates of self-induced dysphoria
53. Gender differences in regional cerebral blood flow during transient self-induced sadness or happiness
54. Neuroanatomical correlates of externally and internally generated human emotion
55. The functional neuroanatomy of major depression: An fMRI study using an emotional activation paradigm
56. Functional neuroanatomy of CCK-4-induced anxiety in normal healthy volunteers
57. Selective pharmacological activation of limbic structures in human volunteers: A positron emission tomography study
58. A functional anatomy of anticipatory anxiety
59. Plasma tryptophan levels and tryptophan/neutral amino acid ratios in obsessive-compulsive patients with and without depression
60. Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse
61. Dorsolateral prefrontal cortex dysfunction in the major psychoses: Symptom or disease specificity?
62. Hypofrontality and negative symptoms in major depressive disorder
63. Limbic-cortical dysregulation: A proposed model of depression
64. Brain metabolic changes associated with symptom factor improvements in major depressive disorder